Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Cast & Crew in the transaction while Goodwin advised TA Associates and Backstage Holdings. Cast & Crew, a leading end-to-end cloud-based platform...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis and Gernandt & Danielsson advised Cint Group AB on the deal, while Goodwin Procter represented Lucid Holdings, LLC. Cint Group AB (publ), a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Toast, Inc. on the deal while Sullivan & Cromwell represented the underwriters. Toast, Inc. (NYSE: TOST) announced its initial public offering of 25,000,000 shares...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised G Squared Ascend I on the deal. Latham & Watkins represented Transfix. G Squared Ascend I (NYSE: GSQD), a special purpose acquisition company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
Latham and Watkins advised Avery Dennison, while Goodwin Procter advised Charlesbank. Cleary Gottlieb represented Goldman Sachs as financial advisor to Avery Dennison in the transaction. Avery...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Pear Therapeutics on the deal. Pear Therapeutics announced its definitive business combination agreement with Thimble Point Acquisition Corp. (Nasdaq: THMA), a special purpose...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Charlesbank Capital Partners on the deal. Charlesbank Capital Partners, a middle-market private investment firm, announced that an affiliated fund has made a significant...
You must be a Standard 1 Year member to access this content.
